Alimera Sees Black for 2018

Alimera Sciences’ Iluvien insert for treatment of diabetic macular edema is making headway in the market, CEO Dan Myers said at the Company Showcase 3 session at OIS@AAO 2017. Q3 revenue grew 18% this year, he pointed out, while end-user demand for Iluvien (fluocinoloneacetonide) grew 9 percent. Meanwhile, Alimera recently acquired rights for Iluvien for treatment of posterior uveitis in Europe, the Middle East, and Africa, and plans to file for that indication in 17 European Union countries next year, Myers said. It will start reporting revenue from posterior uveitis in Q1 2019.